SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 Weeks in DAA-naïve patients: an integrated analysis of the POLARIS-1, PO... von Roberts, S.K, Cooper, C.L, Lawitz, E, Reddy, K.R, Thompson, A.J, Zeuzem, S, Jacobson, I.M, Ruane, P, Hyland, R.H, Stamm, L.M, Han, L, Brainard, D.M, Bräu, N, Asselah, T, Willems, B.E, Flamm, S, Bourlière, M, Foster, G.R, Gane, E.J, Manns, M, Gordon, S.C, Kowdley, K

Volltext

The safety and tolerability of SOF/VEL/VOX for 8 or 12 weeks in >1,000 patients treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 studies: an integrated analysis von Manns, M, Gane, E.J, Willems, B.E, Roberts, S.K, Flamm, S, Bourliére, M, Asselah, T, Alric, L, Hyland, R.H, Stamm, L.M, Huang, K.C, Brainard, D.M, Khalili, M, Foster, G.R, Gordon, S.C, Reddy, K.R, Zeuzem, S, Jacobson, I.M, Cooper, C.L, Thompson, A.J, Kowdley, K, Lawitz, E

Volltext

SAT-236 - The safety and tolerability of SOF/VEL/VOX for 8 or 12 weeks in >1,000 patients treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 studies: an integrated analy... von Manns, M., Gane, E.J., Willems, B.E., Roberts, S.K., Flamm, S., Bourliére, M., Asselah, T., Alric, L., Hyland, R.H., Stamm, L.M., Huang, K.C., Brainard, D.M., Khalili, M., Foster, G.R., Gordon, S.C., Reddy, K.R., Zeuzem, S., Jacobson, I.M., Cooper, C.L., Thompson, A.J., Kowdley, K., Lawitz, E.

Volltext

SAT-280 - SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 Weeks in DAA-naïve patients: an integrated analysis of the POL... von Roberts, S.K., Cooper, C.L., Lawitz, E., Reddy, K.R., Thompson, A.J., Zeuzem, S., Jacobson, I.M., Ruane, P., Hyland, R.H., Stamm, L.M., Han, L., Brainard, D.M., Bräu, N., Asselah, T., Willems, B.E., Flamm, S., Bourlière, M., Foster, G.R., Gane, E.J., Manns, M., Gordon, S.C., Kowdley, K.

Volltext